- Home
- PSTV vs NSRX Comparison
PSTV vs NSRX Comparison
Compare PSTV & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- NSRX
- Stock Information
- Founded
- PSTV 1996
- NSRX 2019
- Country
- PSTV United States
- NSRX Israel
- Employees
- PSTV N/A
- NSRX N/A
- Industry
- PSTV Medical/Dental Instruments
- NSRX Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- NSRX Health Care
- Exchange
- PSTV Nasdaq
- NSRX Nasdaq
- Market Cap
- PSTV 61.1M
- NSRX 65.7M
- IPO Year
- PSTV N/A
- NSRX 2025
- Fundamental
- Price
- PSTV $0.61
- NSRX $7.00
- Analyst Decision
- PSTV Strong Buy
- NSRX Strong Buy
- Analyst Count
- PSTV 4
- NSRX 1
- Target Price
- PSTV $7.25
- NSRX $22.00
- AVG Volume (30 Days)
- PSTV 5.7M
- NSRX 3.3K
- Earning Date
- PSTV 10-30-2025
- NSRX 12-09-2025
- Dividend Yield
- PSTV N/A
- NSRX N/A
- EPS Growth
- PSTV N/A
- NSRX N/A
- EPS
- PSTV N/A
- NSRX N/A
- Revenue
- PSTV $5,258,000.00
- NSRX N/A
- Revenue This Year
- PSTV $9.91
- NSRX N/A
- Revenue Next Year
- PSTV $1.06
- NSRX N/A
- P/E Ratio
- PSTV N/A
- NSRX N/A
- Revenue Growth
- PSTV N/A
- NSRX N/A
- 52 Week Low
- PSTV $0.16
- NSRX $5.90
- 52 Week High
- PSTV $2.31
- NSRX $9.99
- Technical
- Relative Strength Index (RSI)
- PSTV 57.26
- NSRX N/A
- Support Level
- PSTV $0.48
- NSRX N/A
- Resistance Level
- PSTV $0.63
- NSRX N/A
- Average True Range (ATR)
- PSTV 0.05
- NSRX 0.00
- MACD
- PSTV 0.01
- NSRX 0.00
- Stochastic Oscillator
- PSTV 86.96
- NSRX 0.00
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.